Article
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
American journal of hematology - 1 Feb 2018
Abeykoon Jithma P, Paludo Jonas, King Rebecca L, Ansell Stephen M, Gertz Morie A, LaPlant Betsy R, Halvorson Alese E, Gonsalves Wilson I, Dingli David, Fang Hong, Rajkumar S Vincent, Lacy Martha Q, He Rong, Kourelis Taxiarchis, Reeder Craig B, Novak Anne J, McPhail Ellen D, Viswanatha David S, Witzig Thomas E, Go Ronald S, Habermann Thomas M, Buadi Francis K, Dispenzieri Angela, Leung Nelson, Lin Yi, Thompson Carrie A, Hayman Suzanne R, Kyle Robert A, Kumar Shaji K, Kapoor Prashant
Abstract excerpt
Waldenström macroglobulinemia (WM) is an immunoglobulin M-associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P . Owing to low prevalence of the wild-type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10-fold increased risk of mortality in this subgroup compared to patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.